BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

CYTK upcoming catalysts

Cytokinetics: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 2 FDA event(s). Subscribe to CYTK (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-11-13FDA approvalapprovedCYTOKINETICS CYTKMYQORZOApproved 2026-11-13: MYQORZO (NDA219083 SUPPL2)
2025-12-19FDA approvalapprovedCYTOKINETICS CYTKMYQORZOApproved 2025-12-19: MYQORZO (NDA219083 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09 est.P2Cytokinetics CYTKNCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFSymptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)recruiting60
2026-08-31P3Cytokinetics CYTKNCT06081894 A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)Symptomatic Non-Obstructive Hypertrophic Cardiomyopathyactive not recruiting500

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.